Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013)

Halozyme Therapeutics (HALO) reported Capital Leases of $2.6 million for Q3 2013, up 21.43% quarter-over-quarter from $2.1 million in Q2 2013.

Halozyme Therapeutics (HALO) Capital Leases (2012 - 2013) Analysis & Trends

Halozyme Therapeutics (HALO) has 2 years of Capital Leases data on file, last reported at $2.6 million in Q3 2013.

Capital Leases for Q3 2013 came in at $2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2013 was $2.6 million (changed N/A YoY), and the FY2012 annual result was $1.4 million, changed N/A from the prior year.
Capital Leases climbed to $2.6 million in Q3 2013 per HALO's latest filing, from $2.1 million in the prior quarter.
Over five years, Capital Leases peaked at $2.6 million in Q3 2013 and troughed at $1.4 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Halozyme Therapeutics	8.24 Bn	7.92 Bn	297.47 Mn

Download Data